Alzheimer's Disease and Parkinson's Disease
Open accessThe DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Although most cases of Alzheimer's and Parkinson's disease are sporadic, some cases are clearly familial. This review, part of the Genomic Medicine series, examines the genetics of these familial forms. Although the inherited forms are rare, the knowledge derived from investigating their pathobiology has improved our understanding of the pathobiology of the more common, sporadic forms of the diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general terms, neurodegenerative diseases are thought to be driven by the accumulation of neurotoxic material such as amyloid beta (Aβ) or myelin debris in the central nervous system (CNS) (Nussbaum and Ellis, 2003; Trapp and Nave, 2008).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Nussbaum and Ellis, 2003
In the citing paper
“PD pathology is mainly characterized by loss of neurons from the substantia nigra pars compacta in association with the accumulation of ubiquitinated alpha synuclein and other proteins in cytoplasmic inclusions (Lewy bodies) and thread-like proteinaceous inclusions within neurites (Lewy neuritis).”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“However, Lewy bodies are also seen in the cerebral cortex, brainstem nuclei, limbic system, sympathetic ganglia, nucleus basalis of Meinert and myenteric plexus [4].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“This review is focused on the potential of herbal medicine in AD since it is responsible for more than two-thirds of all dementia cases [5,6].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [6]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 4×
“Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Self-citationMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Research works printed but not linked: 5
- 10.1001/archinte.151.5.989 · doi:10.1001/archinte.151.5.989 · Paper page
- Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth–Heinemann, 1998:285-304.
- Duvoisin RC, 1996, Adv Neurol, 69, 33
- Louis ED, 1996, Adv Neurol, 69, 311
- Matsumine H, 1997, Am J Hum Genet, 60, 588
Cited by
Items 501–600 of 1,000
Piątkowska‐Chmiel, I., Gawrońska‐Grzywacz, M., Popiołek, Ł. P., Herbet, M., & Dudka, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-10187-y · Cited by 36
Interactogeneous: Disease Gene Prioritization Using Heterogeneous Networks and Full Topology Scores
Gonçalves, J. P., Francisco, A. P., Moreau, Y., & Madeira, S. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049634 · Cited by 37
Yi, L., Wu, T., Luo, W., Zhou, W., & Wu, J. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.125332 · Cited by 37
“Clinically, Alzheimer’s disease presents with anterograde episodic memory impairments, intellectual disturbances, language problems, and decline in other cognitive domains([3-4]).”
BackgroundA New Era of Clinical Dopamine Transporter Imaging Using 123I-FP-CIT
Park, E. (2012) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.112.111617 · Cited by 35
Zou, Y. F., Qian, Z., Sun, Y., Wei, G., & Zhang, Q. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b08652 · Cited by 35
Kim, D., Hwang, H., Choi, S., Kwon, S. H., Lee, S.-H., Park, J. H., Kim, S., & Ko, H. S. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0538-9 · Cited by 36
“Parkinson’s Disease (PD) is a neurodegenerative disorder that affects approximately 1-2% of the elderly population [33].”
BackgroundMajor histocompatibility complex and sporadic Alzheimer's disease: a critical reappraisal
Candore, G., Balistreri, C. R., Colonna‐Romano, G., Lio, D., & Caruso, C. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2003.10.027 · Cited by 35
Samizadeh, M., Fallah, H., Toomarisahzabi, M., Rezaei, F., Rahimi-Danesh, M., Akhondzadeh, S., & Vaseghi, S. (2023) · Brain Sciences · doi:10.3390/brainsci13060914 · Cited by 35
“It has been estimated that PD affects at least 1% of the population over the age of 60 [2], rising to 1–3% among persons above 80 years [3].”
BackgroundPuerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model
Jiang, M., Yun, Q., Niu, G., Gao, Y., Shi, F., & Yu, S. (2016) · Genetics and Molecular Research · doi:10.4238/gmr.15047501 · Cited by 35
“The main symptoms of PD include tremor, muscle rigidity, hypokinesia, and postural balance disorders (Nussbaum and Ellis, 2003); while the main pathological characteristics of PD include selective degenerative loss of dopaminergic neurons of the substantia nigra pars compacta and the presence of acidophilous inclusion…”
BackgroundInfluentialNO inhibitory constituents as potential anti-neuroinflammatory agents for AD from Blumea balsamifera
Ma, J., Ren, Q., Dong, B., Shi, Z., Zhang, J., Jin, D., Xu, J., Ohizumi, Y., Lee, D., & Guo, Y. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.12.008 · Cited by 34
Alzheimer’s disease: a tale of two diseases?
Nardini, E., Hogan, R., Flamier, A., & Bernier, G. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308070 · Cited by 36
Soreq, L., Ben‐Shaul, Y., Israel, Z. H., Bergman, H., & Soreq, H. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.021 · Cited by 36
“Parkinson's disease (PD), the second most prevalent age-associated neurodegenerative condition worldwide (Dorsey et al., 2007; Nussbaum and Ellis, 2003), is subject to variations due to environmental and genetic risk factors (Bekris et al., 2010; BenMoyal-Segal et al., 2012; Klein and…”
BackgroundLi, Y., Peng, S.-X., Xu, Y., Lin, S. L., Li, Y., Liu, C., Zhao, H., Wang, L., & Shen, Y. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25749 · Cited by 35
Ferulic acid and benzothiazole dimer derivatives with high binding affinity to β-amyloid fibrils
Byeon, S. R., Jin, Y., Lim, S. J., Lee, J. H., Yoo, K. H., Shin, K. J., Oh, S. J., & Kim, D. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.079 · Cited by 34
Mosholder, A. D., Ma, Y., Akhtar, S., Podskalny, G. D., Feng, Y., Lyu, H., Liao, J., Wei, Y., Wernecke, M., Leishear, K., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21090876 · Cited by 33
Mitochondrial Aconitase and Its Contribution to the Pathogenesis of Neurodegenerative Diseases
Padalko, V., Posnik, F., & Adamczyk, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189950 · Cited by 34
“Parkinson’s disease (PD) is one of the most general progressive NDs, affecting over 0.5–1% of those 65–69 years of age [123].”
BackgroundInfluentialGene–Environment Interaction in Alzheimer’s Disease
Singh, N. K., Chhillar, N., Banerjee, B. D., Bala, K., Mukherjee, A. K., Mustafa, M., & Mitrabasu (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512456067 · Cited by 38
“Alzheimer’s disease (AD) is the most common and progressive neurological disease that results in the irreversible loss of neurons, particularly in the cortex and hippocampus.(1) The clinical hallmarks are progressive impairment in memory, judgement, decision making, orientation to physical surroundings, and language.”
BackgroundParkinson’s Symptoms and Caregiver Burden and Mental Health: A Cross-Cultural Mediational Model
Smith, E. R., Perrin, P. B., Tyler, C. M., Lageman, S. K., & Villaseñor, T. (2019) · Behavioural Neurology · doi:10.1155/2019/1396572 · Cited by 33
“PD is the secondmost common progressive neurodegenerative disease in the United States [3], affecting approximately 1% of individuals over the age of 60 [4].”
BackgroundAdvances in NURR1-Regulated Neuroinflammation Associated with Parkinson’s Disease
Al‐Nusaif, M., Lin, Y., Li, T., Cheng, C., & Le, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416184 · Cited by 34
“5–1% among people aged 60–69 and rising to 1–3% over the age of 80 [2,3].”
BackgroundA new perspective on Alzheimer’s disease: m6A modification
Xia, L., Zhang, F., Li, Y., Mo, Y., Zhang, L., Li, Q., Luo, M., Hou, X., Du, Z., Deng, J., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1166831 · Cited by 34
“There is an association between m6A modification and neural development (Nussbaum and Ellis, 2003).”
BackgroundPotassium channels: Possible new therapeutic targets in Parkinson’s disease
Wang, Y., Yang, P.-L., Tang, J.-F., Lin, J., Cai, X., Wang, X., & Zheng, G. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.05.021 · Cited by 33
“[3] Nussbaum RL, Ellis CE.”
BackgroundBis-styrylpyridine and bis-styrylbenzene derivatives as inhibitors for Aβ fibril formation
Byeon, S. R., Lee, J. H., Sohn, J., Kim, D. C., Shin, K. J., Yoo, K. H., Mook‐Jung, I., Lee, W. K., & Kim, D. J. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.090 · Cited by 37
New non-oral drug delivery systems for Parkinson's disease treatment
Md, S., Haque, S., Sahni, J. K., Baboota, S., & Ali, J. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.556616 · Cited by 33
Viader, A., Wright-Jin, E. C., Vohra, B. P. S., Heuckeroth, R. O., & Milbrandt, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027727 · Cited by 35
Neurorehabilitation in Parkinson disease
Archibald, N. K., Miller, N., & Rochester, L. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52901-5.00037-x · Cited by 33
Huang, Y., Jiang, X.-M., Zhuo, Y., Anwu, T., & Wik, G. (2009) · International Journal of Neuroscience · doi:10.1080/00207450802336774 · Cited by 33
“In industrialized countries the overall prevalence is estimated to be 0.3%, with about 1% of the cases found in the population over 60 years of age (Nussbaum & Ellis, 2003).”
BackgroundInfluentialThe incidence of Parkinson's disease in the North-East of England
Duncan, G. W., Khoo, T. K., Coleman, S. Y., Brayne, C., Yarnall, A. J., O'Brien, J. T., Barker, R. A., & Burn, D. J. (2014) · Age and Ageing · doi:10.1093/ageing/aft091 · Cited by 32
“There are estimated to be 127 000 people living with Parkinson’s disease (PD) in the UK [1], making it the second most common neurodegenerative disorder after Alzheimer’s disease (AD) [2].”
BackgroundGuo, K., Huang, W., Chen, K., Huang, P., Peng, W., Shi, R., He, T., Zhang, M., Wang, H., HU, J. L., et al. (2023) · Aging Cell · doi:10.1111/acel.13937 · Cited by 34
Natalia Silva, P., Furuya, T. K., Sampaio Braga, I., Rasmussen, L. T., de Labio, R. W., Bertolucci, P. H., Chen, E. S., Turecki, G., Mechawar, N., Payão, S. L., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121192 · Cited by 30
Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization
Chung, Y., Lee, H., Initiative, T. A. D. N., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowki, J. Q., Toga, A. W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94048-0 · Cited by 35
Cryo-EM structures and transport mechanism of human P5B type ATPase ATP13A2
Chen, X., Zhou, M., Zhang, S., Yin, J. Y., Zhang, P., Xuan, X., Wang, P., Liu, Z., Zhou, B., & Yang, M. (2021) · Cell Discovery · doi:10.1038/s41421-021-00334-6 · Cited by 33
Wei, L., Yu, X., Li, H., Zhu, M., Pu, D., Lü, Q., Bao, Y., & Zu, Y. (2022) · Scientia Horticulturae · doi:10.1016/j.scienta.2022.111663 · Cited by 32
The correlation between Toxoplasma gondii infection and Parkinson’s disease: a case-control study
Oskouei, M. M., Hamidi, F., Talebi, M., Farhoudi, M., Taheraghdam, A., Kazemi, T., Sadeghi-Bazargani, H., & Fallah, E. (2016) · Journal of Parasitic Diseases · doi:10.1007/s12639-014-0595-3 · Cited by 28
Chekani, F., Bali, V., & Aparasu, R. R. (2015) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2015.09.007 · Cited by 32
Seguella, L., Capuano, R., Sarnelli, G., & Esposito, G. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1612744 · Cited by 35
Neuroproteomics as a promising tool in Parkinson’s disease research
Pienaar, I. S., Daniels, W. M. U., & Götz, J. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0070-3 · Cited by 34
The distribution of cerebrovascular amyloid in Alzheimer’s disease varies with ApoE genotype
Trembath, D., Ervin, J. F., Broom, L., Szymanski, M., Welsh-Bohmer, K., Pieper, C., & Hulette, C. M. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0162-9 · Cited by 31
APOE and LRPAP1 gene polymorphism and risk of Parkinson’s disease
Singh, N. K., Banerjee, B. D., Bala, K., Mitrabasu, Dung Dung, A. A., & Chhillar, N. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1651-6 · Cited by 31
Zhou, W., Xia, S., Wang, C., Yang, Q., Verkhratsky, A., & Niu, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07893-6 · Cited by 31
Sibanyoni, M. N., Chaudhary, S. K., Chen, W., Adhami, H., Combrinck, S., Maharaj, V. J., Schuster, D., & Viljoen, A. M. (2020) · Fitoterapia · doi:10.1016/j.fitote.2020.104650 · Cited by 34
Responsive Expression of MafF to β-Amyloid-Induced Oxidative Stress
Wang, X., Zhang, Y., Wan, X., Guo, C., Cui, J., Sun, J., & Li, L. (2020) · Disease Markers · doi:10.1155/2020/8861358 · Cited by 33
“Aβ is produced by cleavage of the transmembrane glycoprotein amyloid precursor protein (APP) through the sequential actions of βsecretases and presenilin-dependent γ-secretases [16].”
BackgroundNutraceutical based SIRT3 activators as therapeutic targets in Alzheimer's disease
Govindarajulu, M., Ramesh, S., Neel, L. T., Fabbrini, M., Buabeid, M. A., Fujihashi, A., Dwyer, D., Lynd, T. O., Shah, K., Mohanakumar, K. P., et al. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.104958 · Cited by 31
Intracerebral microdialysis during deep brain stimulation surgery
Kilpatrick, M., Church, E. W., Danish, S. F., Stiefel, M., Jaggi, J. L., Halpern, C. H., Kerr, M., Maloney, E., Robinson, M. B., Lucki, I., et al. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.04.013 · Cited by 32
“In the nited States it is second only to Alzheimer’s as the most common eurodegenerative disorder (Nussbaum and Ellis, 2003).”
Therapeutic History of Parkinson's Disease in Chinese Medical Treatises
Zheng, G. (2009) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2009.0101 · Cited by 31
Detection of a sleep disorder predicting Parkinson's disease
Hansen, I. H., Marcussen, M., Christensen, J. A. E., Jennum, P., & Sørensen, H. B. D. (2013) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2013.6610868 · Cited by 31
LRRK2 in Transcription and Translation Regulation: Relevance for Parkinson’s Disease
Dorval, V., & Hébert, S. S. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00012 · Cited by 35
Pająk, B., Kania, E., & Orzechowski, A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1805304 · Cited by 40
Bee venom for the treatment of Parkinson’s disease: How far is it possible?
Awad, K., Abushouk, A. I., Abdelkarim, A., Mohammed, M., Negida, A., & Shalash, A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.065 · Cited by 34
Blomqvist, M. E.-L., Silburn, P. A., Buchanan, D. D., Blennow, K., Mellick, G. D., Brookes, A. J., Andreasen, N., Pedersen, N. L., & Prince, J. A. (2004) · Neurogenetics · doi:10.1007/s10048-004-0173-4 · Cited by 31
“Mutations in APP, PSEN1, and PSEN2 in AD [7] and SNCA, PARKIN, and DJ-1 in PD [8] are known to underlie rare mendelian forms of these diseases, but few genetic risk factors for their more-common, sporadic forms have been identified.”
BackgroundPARKINSON’S DISEASE, AUTOIMMUNITY, AND OLFACTION
Benkler, M., Agmon‐Levin, N., & Shoenfeld, Y. (2009) · International Journal of Neuroscience · doi:10.3109/00207450903178786 · Cited by 30
“Parkinson’s disease (PD) is a common progressive neurodegenerative disorder, with a prevalence of 0.5%–1% among elderly populations, rising up to 3% over the age of 80 (Nussbaum & Ellis, 2003).”
BackgroundInfluentialProtective effect of tangeritin in transgenic Drosophila model of Parkinson rsquo s disease
Siddique, Y. H. (2016) · Frontiers in Bioscience-Elite · doi:10.2741/e784 · Cited by 30
“million individuals are suffering from PD worldwide and the number is increasing per day (4).”
BackgroundÁlvarez, I., Latorre, J., Aguilar, M., Pástor, P., & Lloréns, R. (2020) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-020-00770-7 · Cited by 33
“Background Parkinson’s disease (PD) is a neurodegenerative disease, characterized by motor impairments with particular impacts on posture and gait, leading to postural instability and falls [1].”
BackgroundHispanic Perspectives on Parkinson’s Disease Care and Research Participation
Damron, L., Litvan, I., Bayram, E., Berk, S., Siddiqi, B., & Shill, H. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210231 · Cited by 30
Callens, M., Loncke, J., & Bultynck, G. (2022) · Cells · doi:10.3390/cells11121963 · Cited by 32
Genetics, family systems, and multicultural influences.
Rolland, J. S. (2006) · Families Systems & Health · doi:10.1037/1091-7527.24.4.425 · Cited by 34
Evaluation of PINK1 variants in Indian Parkinson's disease patients
Biswas, A., Sadhukhan, T., Majumder, S., Misra, A. K., Das, S. K., Ray, K., & Ray, J. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.10.005 · Cited by 30
“Parkinson's disease (PD) is the second most common neurodegenerative disorder [1].”
BackgroundStructure-based design and synthesis of macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors
Machauer, R., Veenstra, S. J., Rondeau, J., Tintelnot‐Blomley, M., Betschart, C., Neumann, U., & Paganetti, P. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.01.036 · Cited by 33
An Optimized Method for Histological Detection of Dopaminergic Neurons in Drosophila melanogaster
Drobysheva, D., Ameel, K. N., Welch, B. M., Ellison, E., Chaichana, K., Hoang, B., Sharma, S., Neckameyer, W. S., Srinakevitch, I., Murphy, K. J., et al. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.951137 · Cited by 30
Dementia and Parkinson's Disease: Similar and Divergent Challenges in Providing Palliative Care
van der Steen, J. T., Lennaerts, H. H., Hommel, D., Augustijn, B., Groot, M. M., Hasselaar, J. G. J., Bloem, B. R., & Koopmans, R. T. C. M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00054 · Cited by 34
Yarnall, A. J., Archibald, N. K., & Burn, D. J. (2012) · Medicine · doi:10.1016/j.mpmed.2012.07.008 · Cited by 30
In search of genes involved in neurodegenerative disorders
Pardo, L. M., & van Duijn, C. M. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2005.06.006 · Cited by 35
Santos, J. M. G., Gavrila, D., Antúnez, C., Tormo, M.-J., Salmerón, D., Carles, R., Veiga, J. J., Parrilla, G., del Río, S. T., Fortuna, L., et al. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000140624 · Cited by 31
“Dementia is an increasingly common diagnosis in developed countries. Among all types of dementia, the most frequent is Alzheimer’s disease [ ,”
BackgroundChanges in Body Composition Before and After Parkinson's Disease Diagnosis
Song, S., Luo, Z., Li, C., Huang, X., Shiroma, E. J., Simonsick, E. M., & Chen, H. (2021) · Movement Disorders · doi:10.1002/mds.28536 · Cited by 32
Age-at-onset linkage analysis in Caribbean Hispanics with familial late-onset Alzheimer’s disease
Lee, J. H., Barral, S., Cheng, R., Chacón, I. J., Santana, V., Williamson, J., Lantigua, R., Medrano, M. A., Jiménez‐Velázquez, I. Z., Stern, Y., et al. (2007) · Neurogenetics · doi:10.1007/s10048-007-0103-3 · Cited by 29
Torres-Bugeau, C. M., Ávila, C. L., Raisman‐Vozari, R., Papy-García, D., Itri, R., Barbosa, L. R. S., Cortez, L. M., Sim, V. L., & Chehín, R. N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.303503 · Cited by 29
Luo, Z., Ahlers‐Dannen, K. E., Spicer, M. M., Yang, J., Alberico, S. L., Stevens, H. E., Narayanan, N. S., & Fisher, R. A. (2019) · JCI Insight · doi:10.1172/jci.insight.126769 · Cited by 35
Silva, T., Borges, F., Serrão, P., & Soares-da-Silva, P. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.015 · Cited by 29
Chakraborty, S., Chatterjee, B., & Basu, S. (2012) · Biophysical Chemistry · doi:10.1016/j.bpc.2012.05.003 · Cited by 30
AATF protects neural cells against oxidative damage induced by amyloid β-peptide
Xie, J., & Guo, Q. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.02.003 · Cited by 32
“…of amyloid h-peptide (Ah) are defining features of Alzheimer’s disease (AD) (Behl and Moosmann, 2002; Bothwell and Giniger, 2000; Butterfield, 2002; Citron, 2002; Hardy and Selkoe, 2002; Lee, 2002; Nussbaum and Ellis, 2003; Puglielli et al., 2003; Selkoe, 1998, 2000; Yuan and Yankner, 2000).”
BackgroundXiong, B., Huang, X., Shen, L., Shen, J., Luo, X., Shen, X., Jiang, H., & Chen, K. (2004) · PubMed · Cited by 30
Alcock, L., Galna, B., Hausdorff, J. M., Lord, S., & Rochester, L. (2018) · Gait & Posture · doi:10.1016/j.gaitpost.2018.01.030 · Cited by 30
Smith, E. R., Perrin, P. B., Tyler, C. M., Lageman, S. K., & Villaseñor, T. (2020) · Brain and Behavior · doi:10.1002/brb3.1753 · Cited by 28
“Parkinson's disease (PD) is a neurodegenerative illness affecting 1–2 individuals per 1,000 of the population (Tysnes & Storstein, 2017), or about 1% of those in the 65–69 age range and 1% to 3% of those aged 80 and above (Nussbaum & Ellis, 2003).”
BackgroundEghlidos, Z., Rahimian, Z., Vadiee, G., & Jahangiri, S. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13652 · Cited by 30
Photo‐activity induced by amyloidogenesis
Tcherkasskaya, O. (2007) · Protein Science · doi:10.1110/ps.062578307 · Cited by 29
Candidate biomarkers for Parkinson's disease
Khodadadian, A., Hemmati-Dinarvand, M., Kalantary‐Charvadeh, A., Ghobadi, A., & Mazaheri, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.026 · Cited by 33
Examination of the UPDRS Bradykinesia Subscale: Equivalence, Reliability and Validity
Buck, P. O., Wilson, R. E., Seeberger, L., Conner, J. B., & Castelli‐Haley, J. (2011) · Journal of Parkinson s Disease · doi:10.3233/jpd-2011-11035 · Cited by 28
AI-assisted ophthalmic imaging for early detection of neurodegenerative diseases
Tukur, H. N., Uwishema, O., Akbay, H., Sheikhah, D., & Correia, I. F. S. (2025) · International Journal of Emergency Medicine · doi:10.1186/s12245-025-00870-y · Cited by 30
Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson’s Disease
Frahm, N., Hecker, M., & Zettl, U. K. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210728102832 · Cited by 31
Leveraging ANFIS with Adam and PSO optimizers for Parkinson's disease
Pasha, A., Ahmed, S. T., Painam, R. K., Mathivanan, S. K., Karthikeyan, P. P., Mallik, S., & Qin, H. H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30241 · Cited by 32
“It is the second most common neurodegenerative disorder after Alzheimer ’ s disease (AD) [1].”
BackgroundCharacterization and Biological Evaluation of Diterpenoids from Casearia graveolens
Xu, J., Ji, F., Sun, X., Cao, X., Li, S., Ohizumi, Y., & Guo, Y. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00583 · Cited by 27
Association Between Serum Zinc Levels and the Risk of Parkinson’s Disease: a Meta-Analysis
Sun, H., Liu, X., Ge, H., Wang, T., Wang, Y., & Li, W. (2017) · Biological Trace Element Research · doi:10.1007/s12011-017-0941-2 · Cited by 27
“Circumspectly, the prevalence of PD is expected to rise steadily in the future [3].”
BackgroundKlietz, M., Rippena, L., Lange, F., Tulke, A., Paracka, L., Dressler, D. W., & Wegner, F. (2019) · International Psychogeriatrics · doi:10.1017/s1041610219000206 · Cited by 31
“Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide (Nussbaum and Ellis, 2003) with an estimated increase of patients in the future due to demographic change (Bach et al.”
BackgroundSolla, P., Cannas, A., Marrosu, F., & Marrosu, M. G. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5190 · Cited by 33
Huang, Y.-F., Chou, Y., Yeh, C., Hu, C., Cherng, Y., Chen, T.-L., & Liao, C. (2016) · Medicine · doi:10.1097/md.0000000000003196 · Cited by 29
Huang, H.-J., Lee, C.-C., & Chen, C. Y. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/830490 · Cited by 26
Tavakol, S., Musavi, S. M. M., Tavakol, B., Hoveizi, E., Ai, J., & Rezayat, S. M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0006-0 · Cited by 26
Depciuch, J., Zawlik, I., Skrzypa, M., Pająk, J., Potocka, N., Łach, K., Bartosik-Psujek, H., Koziorowska, A. M., Kaznowska, E. B., & Cebulski, J. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181008 · Cited by 27
“) are observed in the brain[22].”
Preconditioning as a Potential Strategy for the Prevention of Parkinson’s Disease
Golpich, M., Rahmani, B., Ibrahim, N. M., Dargahi, L., Mohamed, Z., Raymond, A. A., & Ahmadiani, A. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8689-6 · Cited by 27
Wang, N., Wang, Y., Yu, G., Yuan, C., & Ma, J. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0541-z · Cited by 29
Novel therapy in Parkinson's disease: adenosine A2Areceptor antagonists
Szabó, N., Kincses, Z. T., & Vécsei, L. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.557066 · Cited by 27
Phytochemical constituents from Melicope pteleifolia that promote neurite outgrowth in PC12 cells
Xu, J., Sun, X., Liu, X., Peng, M., Li, S., Jin, D., Lee, D., Bartlam, M. G., & Guo, Y. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.03.011 · Cited by 26
Voice quality outcomes of idiopathic Parkinson's disease medical treatment: A systematic review
Lechien, J. R., Blecic, S. A., Huet, K., Delvaux, V., Piccaluga, M., Roland, V., Harmegnies, B. G., & Saussez, S. (2018) · Clinical Otolaryngology · doi:10.1111/coa.13082 · Cited by 28
Überbacher, C., Obergasteiger, J., Volta, M., Venezia, S., Müller, S., Pesce, I., Pizzi, S., Lamonaca, G., Picard, A., Cattelan, G., et al. (2019) · Stem Cell Research · doi:10.1016/j.scr.2019.101656 · Cited by 26
“Parkinson ́s disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, and the most common neurodegenerative movement disorder (Nussbaum and Ellis 2003).”
BackgroundGenetics of neurological disorders
Faghihi, M. A., Mottagui‐Tabar, S., & Wahlestedt, C. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.3.317 · Cited by 26
Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers
Suk, K. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.6 · Cited by 31
Clarke, G. D., & Lumsden, C. J. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.10.028 · Cited by 29
Lee, J. H., Han, K., & Gee, H. Y. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.012 · Cited by 25
Ghosh, R., Cingireddy, A. R., Melapu, V. K., Joginipelli, S., & Kar, S. (2021) · International Journal of Quantitative Structure-Property Relationships · doi:10.4018/ijqspr.2021040103 · Cited by 25
The GBA, DYRK1A and MS4A6A polymorphisms influence the age at onset of Chinese Parkinson patients
Fan, K., Tang, B., Wang, Y., Kang, J.-F., Li, K., Liu, Z., Sun, Q., Xu, Q., Yan, X., & Guo, J. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.04.014 · Cited by 25
Myeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 27
Metadata
- Authors
- Nussbaum, R. L., & Ellis, C. E.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Nussbaum, Robert L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1356-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149522871
- Cited by
- 1,351
- References
- 107
- Citations by year
- 2026: 25 · 2025: 55 · 2024: 75 · 2023: 74 · 2022: 80 · 2021: 82 · 2020: 80 · 2019: 83 · 2018: 74 · 2017: 74 · 2016: 63 · 2015: 54 · 2014: 65 · 2013: 46 · 2012: 66
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, Parkinson's disease, genetic susceptibility, inherited neurodegenerative disorders
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Humans, Molecular Sequence Data, Nerve Tissue Proteins, Substantia Nigra, Prevalence, Amyloid beta-Protein Precursor, Lewy Bodies, Mutation, Missense, Parkinsonian Disorders, Synucleins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.